Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft.
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft.
复制标题
DOI:
10.1158/0008-5472.can-08-4120
复制
发表时间:
2009-04-15
期刊:
影响因子:
11.2
通讯作者:
Bhujwalla ZM
中科院分区:
文献类型:
--
作者:
Krishnamachary B;Glunde K;Wildes F;Mori N;Takagi T;Raman V;Bhujwalla ZM
Elevated phosphocholine (PC) and total choline metabolites are widely established characteristics of most cancer cells including breast cancer. Effective silencing of choline kinase (chk), the enzyme that converts choline to phosphocholine, is associated with reduced tumor growth. The functional importance and down regulation of chk using RNAi has been previously established. Here, we report on the preclinical evaluation of lentiviral vector-mediated downregulation of choline kinase (chk) using short hairpin RNA (shRNA), in established tumors derived from human breast cancer cells. Concentrated lentivirus expressing shRNA against chk was injected intravenously in the tail vein of MDA-MB-231 tumor bearing female severe combined immunodeficient (SCID) mice. Transduction efficiency in cells and tumors in vivo, was assessed optically by enhanced green fluorescent protein (EGFP) expression and additionally from chk mRNA and protein levels. An 80% reduction in chk mRNA and protein was achieved following almost 100% transduction efficiency in cells. Post-transduction with chk-shRNA, 1H magnetic resonance spectroscopy (MRS) of cell and tumor extracts showed decreases in PC and total choline levels (P < 0.01 and 0.05 respectively) in comparison to controls. PC levels were monitored non-invasively by 31P MRS in tumors, and by 1H MRS in cell and tumor tissue extracts. Noninvasive 31P MR spectra of chk-shRNA transduced tumors in vivo showed lower PC and phosphomonoester (PME) levels that were associated with reduced tumor growth and proliferation. This study demonstrates the use of lentiviral vectors to target chk in a human breast cancer xenograft, and noninvasive MRS detection of this targeting.